Company profile: Patch Biosciences
1.1 - Company Overview
Company description
- Provider of machine-designed DNA and an AI platform for sequence design to engineer more effective and durable gene therapies, leveraging large-scale DNA synthesis and machine learning. Offers synthetic promoter and untranslated region engineering, validated muscle promoters, and robust RNA UTRs for genetic and RNA-based medicines.
Products and services
- AI platform for sequence design: A machine-learning-driven system that architects machine-designed DNA and optimizes genetic sequences to create more effective, durable genetic medicines via large-scale DNA synthesis
- Validated muscle promoters: Application-validated muscle promoters for genetic medicine applications, delivered to support gene therapy efforts requiring muscle-oriented promoter sequences
- Synthetic promoter and untranslated region (UTR) engineering: Custom-engineered technologies that fabricate synthetic promoters and UTRs to enhance the effectiveness of genetic medicines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Patch Biosciences
Fulcrum Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fulcrum Therapeutics company profile →
GeneThera
HQ: United States
Website
- Description: Provider of biotechnology applying molecular technologies to improve food safety and eradicate zoonotic diseases, including Johne's Disease, Mad Cow Disease, Chronic Wasting Disease, and E.coli, affecting terrestrial, avian, and aquatic animals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneThera company profile →
MyoNexus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital; RNA exon-skipping technologies for rare diseases, particularly Duchenne muscular dystrophy, using PMO with next-generation PPMO in development; gene editing research; and precision genetic medicine platforms for Charcot-Marie-Tooth disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyoNexus Therapeutics company profile →
CropDesign
HQ: Belgium
Website
- Description: Provider of agricultural biotechnology solutions delivering genetic traits for the global seed market and plant-based products. Uses its proprietary TraitMillTM platform to discover traits that improve corn, rice, and other plants; offers crops like corn and rice to the seed market. Founded in 1998, employs more than 70 people at research facilities in Gent, Belgium.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CropDesign company profile →
Razor Genomics
HQ: United States
Website
- Description: Provider of life science research and development focused on novel tests for the diagnosis of lung cancer, based in Brisbane.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Razor Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Patch Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Patch Biosciences
2.2 - Growth funds investing in similar companies to Patch Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Patch Biosciences
4.2 - Public trading comparable groups for Patch Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →